Thrombophilia Market Report 2024 - Market Size, Growth Rate, Major Drivers And Key Trends

The new report published by The Business Research Company, titled "Thrombophilia Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the thrombophilia market size has grown strongly in recent years. It will grow from $15.97 billion in 2023 to $17.23 billion in 2024 at a compound annual growth rate (CAGR) of 7.9%. The thrombophilia market size is expected to see strong growth in the next few years. It will grow to $23.31 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=9439&type=smp

Surge In Elderly Population Propels Growth In The Thrombophilia Market
An increase in the elderly population is expected to propel the growth of the thrombophilia market going forward. The elderly population refers to those aged 65 and up, with the proportion of the dependent population determined as the total elderly and youth population expressed as a ratio of the total population. Thrombophilic risk factors are common in elderly adults and allow for the identification of a population at risk for poor clinical outcomes, hence, the rise in the elderly population will boost the market as it creates demand for thrombophilia drugs. For instance, according to the data released by America's Health Rankings, a US-based organization that evaluates health outcomes, in 2022, more than 56 million adults aged 65 and older account for around 16.9% of the total US population. More than 73.1 million older people are expected by 2030, when the last of the baby boomer generation enters old age. Therefore, the increase in the elderly population is driving the growth of the thrombophilia market.

Groundbreaking Technological Advances And Long-Acting Drugs On The Horizon
Technological advancements are the key trend gaining popularity in the thrombophilia market. Major companies operating in the market are developing innovative technologies to sustain their position in the market. For instance, in 2021, the University of Oslo, a Norway-based public research university, created a brand-new technology known as super albumin that may result in the creation of long-acting drugs and have important consequences for people who suffer from hemophilia, a condition that damages the blood's capacity to clot. The university's research group developed a cutting-edge biomedical technique that can be utilized to produce coagulation factors with a significantly longer half-life than those that are available at present. The starting point is a detailed investigation of a biological mechanism. They were able to produce super albumin, a protein variant that can be coupled with protein-based drugs to extend their bloodstream half-life, using the knowledge they gained from this research.

The thrombophilia market covered in this report is segmented -

1) By Type: Factor V Leiden, Prothrombin 20210, Antiphospholipid Syndrome, Other Type
2) By Drugs: Heparin, Warfarin, Other Drugs
3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration
4) By End-Users: Hospitals, Homecare, Speciality Centres, Other End Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=9439&type=discount

Major companies operating in the thrombophilia market report are Pfizer Inc., F. Hoffmann-La Roche Limited, Mylan N.V., Changzhaou Qianhong Bio-pharma Co. Limited, Fresenius Kabi AG, Hebei Changshan Biochemical Pharmaceutical Co. Limited, Hikma Pharmaceuticals PLC., Novartis AG, Shanghai Fosun Pharmaceutical (Group) Co. Ltd., Shenzhen Hepalink Pharmaceutical Group Co. Limited, Teva Pharmaceutical Industries Limited, Yino Pharma Limited, Aspen Insurance Holdings Limited, Sanofi SA, Eisai Co. Limited, Boehringer Ingelheim GmbH, Siemens, LabCorp, Instrumentation Laboratory SpA, Johnson & Johnson, Laurus Lab, Bristol-Myers Squibb, Roche, Abbott, C. H. Boehringer Sohn, Portola Pharmaceuticals, Daiichi Sankyo, Bayer Group, GlaxoSmithKline plc, CSL Behring .

Contents of the report:
1. Executive Summary
2. Thrombophilia Market Report Structure
3. Thrombophilia Market Trends And Strategies
4. Thrombophilia Market - Macro Economic Scenario
5. Thrombophilia Market Size And Growth
…..
27. Thrombophilia Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/thrombophilia-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.